ArticleOncotarget2016
Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- MetaDE-Based Analysis of circRNA Expression Profiles Involved in Gastric Cancer.Digestive diseases and sciences · 2020Pooled it
- Carbohydrate antigen 72-4 and tumor-associated glycoprotein 72 - tumor marker: Past, present and future.World journal of gastrointestinal pathophysiology · 2026Review
- Article
- Proteomic Analysis of Extracellular Vesicles Reveals Vitronectin and Laminin Subunit Alpha-3 as Candidate Biomarkers for Gastric Cancer.Gut and liver · 2026Article
- Development and validation of a novel blood-based biomarker for gastric cancer triage in chronic dyspepsia.NPJ digital medicine · 2026Article
- Tissue Claudin 18.2 levels as a prognostic factor in gastric adenocarcinomas: A retrospective cohort study.Medicine · 2026Article
- Incomplete TNM Documentation in Gastric Cancer: Frequency, Phenotype, and Treatment Allocation.Diagnostics (Basel, Switzerland) · 2026Article
- Advances in protein microarray-based proteomics for gastric cancer applications in biomarker discovery, molecular subtyping, and precision oncology.Frontiers in oncology · 2026Review
- Review
- Bacteria-derived DNA in serum extracellular vesicles as a biomarker for gastric cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Combined albumin and CEA improve prognostic prediction in resectable gastric cancer.Scientific reports · 2025Article
- Article
- Prediction model based on gut microbiota as a non-invasive tool for gastric cancer diagnosis.Applied microbiology and biotechnology · 2025Article
- The combination of CA125, CA199, CEA, and AFP is an effective diagnostic biomarker for gastric cancer in elderly individuals.World journal of surgical oncology · 2025Article
- Value of serum pepsinogen ratio screening for early gastric cancer and precancerous lesions in Youcheng area.World journal of gastrointestinal surgery · 2024Article
- Identification of an autophagy- and macropinocytosis-related prognostic signature for the prediction of prognosis and therapeutic response in gastric cancer.Genes & genomics · 2024Article
- CRYAB Promotes Colorectal Cancer Progression by Inhibiting Ferroptosis Through Blocking TRIM55-Mediated β-Catenin Ubiquitination and Degradation.Digestive diseases and sciences · 2024Article
- Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer.World journal of gastrointestinal oncology · 2024Article
- Ascites-derived hsa-miR-181a-5p serves as a prognostic marker for gastric cancer-associated malignant ascites.BMC genomics · 2024Article
- Mass spectrometry analysis of intact proteinJournal of Zhejiang University. Science. B · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the clinical significance of multiple serum tumor markers (TMs) in the diagnosis of gastric cancer (GC) and establish an accurate discriminant equation to identify the presence of GC.
resultsThe serum levels of CEA, CA19-9 and CA72-4 were higher in the GC group than in the control group (P < 0.005). The sensitivity of CEA, CA19-9 and CA72-4 in the diagnosis of GC was 20.1-27.6% individually and increased to 48.2% when they were considered in combination. By using the optimal cut-off value, the sensitivity of CEA, CA19-9 and CA72-4 for the diagnosis of GC was improved but remained unsatisfactory. In addition, we developed the equation Y = -2.185 - 0.015 X1 + 0.180 X2 + 1.226 X3 + 1.505 X4 + 2.749 X5 (X1 = Age, X2 = Sex, X3 =CEA, X4 = CA19-9 and X5 = CA72-4) to predict the presence of GC. This has better accuracy and diagnostic efficiency compared to the combination of TMs.
methodsSerum carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9)and cancer antigen 72-4 (CA72-4) levels were measured in a total of 2288 patients with GC and 1869 healthy volunteers or patients with benign gastric diseases. We established a diagnostic equation using a portion of the data (training set), and validate its accuracy using the other portion of the data (testing set) .
conclusionsThe diagnostic equation increases the accuracy rate for the diagnosis of GC and will be helpful in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.